An open label multi facilities cooperation randomized control trial to verify urinary angiotensinogen excretion reducing effect of olmesartan therapy in diabetic nephropathy.
Not Applicable
- Conditions
- Hypertensive type2 diabetic nephropathy patients with chronic kidney disease (CKD)
- Registration Number
- JPRN-UMIN000001618
- Lead Sponsor
- Graduate School of Medicine, Tohoku University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
Not provided
Exclusion Criteria
1) A serum creatinine level is more than 2.5 mg/dl and existence of hematuria. 2) A patient who has received continuous dialysis. 3) With severe diabetic complications such as retinal hemorrhage, neuropathy, and so on. 4) Existence of severe hepatic damages, and cerebrovascular disorders including heart failure. 5) A severe hypertensive patient (BP > 200/110 mmHg). 6) Use of rennin angiotensin system (RAS) inhibitors.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method